Abstract
In this work, a new salt of clofazimine (CFZ) with 4-aminobenzoic acid (PABA is described. CFZ is an antibiotic drug used in the treatment of leprosy. This drug has low absorption when administered orally because of its low water solubility, contributing to the reduction of bioavailability, limiting its application. Towards the augmentation of the bioavailability of CFZ, we propose in this work the development of a salt. The new product CFZ+–PABA– (1:1) was synthesized through liquid assisted grinding method and characterized by powder X-ray diffraction, mid-infrared spectroscopy, and differential scanning calorimetry. The investigations provided evidence of the formation of a new salt. The interaction involves proton transfer between PABA and CFZ forming R21(7) motif in carboxylate region (COO−) of PABA and imines regions (N–H/N+–H) of CFZ. According to the analyses, the stoichiometric ratio of salt formation is 1:1. The salt dissolution profile shows the product is 5.0 folds more soluble than the CFZ free base.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
